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Efforts are being made to develop neuroprotective
agents for recovery and prevention of further
deterioration of brain tissues in patient with
stroke.Granulocyte-colony stimulating factor (GCSF) is
a glycoprotein hormone encoded by a single gene
located on chromosome 17q 11-22. It functions in the
regulation of granulopoiesis& terminal maturation of
neutrophills. It is being used for the treatment of
neutropenia for the production of CD34+
haematopoietic stem cell (HSC) for bone marrow
transplant patients. Neuroprotective effect of GCSF is
being studied in various experimental studies but its
mechanism of action is not well understood and
appears to be multimodal.
What is this study? 
This was a randomized, double blind, placebo-
controlled phase IIB trial for the assessment of safety of
use of GCSF in patients with recent stroke, and also to
study its effect on mobilization of bone marrow
derived haematopoietic stem cells and their fate in
brain tissue.
Who were the participants? 
A total of 60 patients were included from 205 screened
participants between 3-30 days after ischaemic and
haemorrhagic stroke from July 2007 to January 2010 from
a single center. They were divided into two groups in a
ratio of 2:1 in treatment vs. placebo group. Both groups
were well matched for their base line characters and
prognostic factors.
What was the intervention? 
Patients were randomly assigned into treatment and
placebo group. Treatment group was given
Granulocyte- colony stimulating factor (GCSF)10ug/kg
of against a matched saline in placebo group
subcutaneously for 5 days in a double blinded fashion.
All the patients were given an opportunity for
haematopiietc stem cell labeling for another substudy.
Volumetric analysis of infracted tissue in the brain was
also performed in both groups for patients in whom it
was possible.
What was the outcome?
There was no statistical difference between the two
groups in terms of primary outcome e.g. severe adverse
event (SEA) at 90 days, GCSF 37.5% vs. 35%in placebo
group.. There was no difference in the vascular events in
two groups. GCSF increased CD34+ and total white cell
count by 9.5 and 4.2 folds respectively.
Only one participant showed migration of iron labeled
CD34+ cell in the ischaemic stroke lesion. There was a
reduction in the volume of ischaemic lesion in the MRI of
the GCSF treated patients. A subgroup analysis showed
functional improvement in the GCSF treated group as
appeared by improved NIHSS score.
Why is this study important and
noteworthy? 
The author concluded that GCSF administration was safe
in patients with sub-acute stroke. Improvement in the
functional status of GCSF treated patients along with the
stroke lesion volume also favours some neurorepair
properties of GCSF but needs further evaluation.
Mobilization of CD34+ cells to the ischaemic brain lesion
opens future molecular level research question for further
studies.
This trial had avery small sample size which limits the
interpretation of results for a larger group of
population but this provides a solid ground for future
studies in evaluating the efficacy of GCSF as
neuroprotective and repair agent for stroke patients.
Many Phase III trials are required before the implication
of GCSF as neuroprotective agent in the treatment of
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stroke opening a new era for the treatment of this
devastating disease.
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